资料单张
ADCO-AMOCLAV 375 mg (Tablets)
ADCO-AMOCLAV 625 mg (Tablets)
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
ADCO-AMOCLAV 375 mg (Tablets)
ADCO-AMOCLAV 625 mg (Tablets)
COMPOSITION:
ADCO-Amoclav 375 mg: Each tablet contains:
Amoxicillin trihydrate equivalent to
amoxicillin
250 mg
and Potassium clavulanate equivalent to
clavulanic acid
125 mg
Butylhydroxytoluene
(as antioxidant)
0,46% m/m
ADCO-Amoclav 625 mg: Each tablet contains:
Amoxicillin Trihydrate equivalent to amoxicillin
500 mg
and Potassium clavulanate equivalent to clavulanic acid 125 mg
Butylhydroxytoluene
(as antioxidant)
0,46% m/m
PHARMACOLOGICAL CLASSIFICATION:
A 20.1.2 Penicillins
PHARMACOLOGICAL ACTION:
Mechanism of action:
ADCO-Amoclav is a combination of amoxicillin and potassium clavulanate. The amoxicillin component of the
formulation exerts a bactericidal action against many strains of Gram positive and Gram-negative organisms. The
clavulanic acid component has little or no antimicrobial action. It does, however, by inactivation of susceptible beta-
lactamase protect amoxicillin from degradation by beta-lactamase enzymes produced by penicillin resistant strains of
organisms.
Antibacterial Activity
Clavulanic acid is an irreversible inhibitor of beta-lactamases produced by Staphylococcus aureus, Escherichia coli,
Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris , H. influenzae, N. gonorrhoeae and B. fragilis (In-vitro
activity does not necessarily imply in-vivo efficacy). Potassium clavulanate does not inactivate the chromosomally
mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species,
Enterobacter, indole positive Proteus, Providencia species and Serratia marcescens.
Pharma
阅读完整的文件